Canadian clinical trial registry

Go to Health Care Provider version

Centres

Study Description

This study will evaluate the combination of two drugs called favezelimab and pembrolizumab to see how effective and safe it is for treating patients with a cancer called lymphoma. There are various different kinds of lymphoma, this study is for patients with classical Hodgkin, indolent non-Hodgkin or diffuse large B-cell lymphoma. 

Inclusion Criteria

• Participants must be 18 years of age or older 
• Participants must have a diagnosis of:
  • classical Hodgkin lymphoma (cHL)
  • diffuse large B-cell lymphoma (DLBCL)
  • indolent non-Hodgkin lymphoma (iNHL)
• Must have a tumour that can be measured on CT or MRI 
• Participant should be well enough to carry out light daily tasks, e.g., light house work, office work, normal activities

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

This is a Phase 1b/2 study of the drug DAY101 in patients ≥12 years of age with solid tumours or brain tumours that have come back or progressed. This study includes 2 sub-studies, patients in sub-study A will receive the DAY-101 drug and patients in sub-study B will receive "DAY-101" and another drug called pimasertib in combination.

Inclusion Criteria

• Participants must be between 12 to 18 years old
• Participants must have a solid tumour or brain tumour that has come back (relapsed) or progressed 
• Participants must have a qualifying gene change in the tumour (MAPK pathway)
• If enrolled on study, patients and their families must agree to the study requirements by signing an informed consent/assent form

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.

Go to Health Care Provider version

Centres

Study Description

A clinical trial to look at how safe and tolerable the drug RO7428731 is at different doses, how the body processes it, and if there are any early signs of treatment efficacy of RO7428731 in patients with glioblastoma that has the marker EGFRvIII

Via: Clinical Trial – Glioblastoma – Safety, Tolerability, Pharm... (roche.com)

Inclusion Criteria

• Diagnosis of glioblastoma with a tumour expression called EGFRvIII
• Must have completed standard of care therapy prior to joining this study
• Must be up and about at least 70% of their waking hours
• Adequate organ functions prior to start of study treatment
• Willingness to abide by contraceptive measures for the duration of the study.

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team

Go to Health Care Provider version

Centres

Study Description

This is a phase 2 study designed to evaluate the safety of a drug called Lutathera in patients 12 to <18 years old with GEP-NET and PPGL disease. For patients on the study, this drug will be infused 4 times at 8-week intervals. After the infusions are complete, a follow-up period will take place after the last dose for each patient who received at least one dose of Lutathera.

Inclusion Criteria

• Patients must have a diagnosis of GEP-NET or PPGL that has gotten worse or can not be operated on
• Patients must be between 12 to <18 years old at the time of enrollment
• Patients must be up and about for over half of their waking hours
• Patients and their families (as applicable) must agree to sign the written informed consent forms outlined by the study team

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

(from https://forpatients.roche.com/en/trials/cancer/solid-tumors/tumor-agnostic-precision-immuno-oncology-and-somatic-ta-50851.html)

This clinical trial is recruiting people who have advanced solid tumors that cannot be surgically removed. You (or your child) must have had genetic testing on the solid tumors that shows a positive result for one of the genetic changes, also known as biomarkers, being tested in this trial.

The purpose of this clinical trial is to compare the effects, good or bad, of different targeted therapies and immunotherapies in patients with solid tumors that cannot be surgically removed and show specific biomarkers.

To be able to take part in this clinical trial, you (or your child) must have been diagnosed with solid tumors that cannot be surgically removed and show one of the specific biomarkers that are being tested in this study:

• ROS1 fusion-positive tumors
• NTRK1/2/3 fusion-positive tumors
• TMB-high tumors
• ALK fusion-positive
• AKT1/2/3 mutant-positive tumors
• HER2 mutant-positive tumors
• PIK3CA multiple mutant-positive tumors
• BRAF class II mutant or fusion-positive tumors
• BRAF class III mutant-positive tumors
• RET fusion-positive tumors

Your doctor will be able to give you more information on the type of biomarker your solid tumors show. You must be otherwise in good health to take part. You will not be able to take part if you are pregnant or breastfeeding, or if you have received any recent treatment for your cancer. Some of the groups may have other specific requirements. Your doctor will be able to give you more information on this.

Inclusion Criteria

• Less than 18 years of age for cohort E and K
• Age between 12 and 17 years for cohorts E, F and H
• Diagnosis of advanced cancer that has spread to a different part of the body (metastasized) and can’t be removed by an operation (unresectable)
• Participants must be up and about at least 50% of their waking hours
• The cancer must have a specific genetic change in one of the following genes: ROS1, NTRK1/2/3, AKT, PIK3CA, HER2, BRAF, RET, or be TMB-high

Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This is a Phase 3 study to evaluate how safe and effective a drug called tovorafenib is when compared to standard of care chemotherapy. This study is for patients with low-grade glioma (LGG) who have a genetic mutation called a RAF alteration. 

Inclusion Criteria

• Patients must be under 25 years of age to participate
• Must have a diagnosis of a low grade glioma that has RAF alteration 

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

This study looks to assess if additional intensive treatment for patients with medulloblastoma and other embryonal brain tumors improves outcomes without adding significant short or long-term side effects. 

Inclusion Criteria

Patients 10 years of age of less with a diagnosis of medulloblastoma or CNS embryonal tumors of the brain or spinal cord. Any stage of medulloblastoma or CNS embryonal tumor in children less than 6 years old are eligible, whereas only high risk patients from 6-10 years of age are eligible. 

Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment.

Inclusion Criteria

• Participants must be ≤ 18 years of age (Part A and B only) or < 21 years of age (Part C only)
• Must have adequate body surface area (BSA)
• Participants must have a solid tumour (excluding lymphoma) that has come back or progressed on standard therapies
• PART C ONLY: Participants with neuroblastoma that has come back or progressed on standard therapies
• Participants must be able to be up and about for at least half of their waking hours
• Participants of reproductive potential must not be pregnant within 7 days of and during the study
• Ability to swallow
• Participants and their families (as applicable) must agree to the study assessments by signing an informed consent form

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team